John Seymour

Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial.

Ie-Wen Sim, Gelsomina L Borromeo, Claudine Tsao, Rita Hardiman, Michael S Hofman, Christian Papatziamos Hjelle, Musib Siddique, Gary JR Cook, John F Seymour, Peter R Ebeling

Journal article  |  2020  |  Journal of Clinical Oncology

PURPOSE: Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent but morbid and potentially serious condition associa..

Response in patients with BIRC3-mutated relapsed/refractory chronic lymphocytic leukemia treated with fixed-duration venetoclax and rituximab.

Arnon P Kater, Yanwen Jiang, Brenda Chyla, John F Seymour

Journal article  |  2020  |  Haematologica

BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.

Victor S Lin, Thomas E Lew, Sasanka M Handunnetti, Piers Blombery, Tamia Nguyen, David A Westerman, Bryone J Kuss, Constantine S Tam, Andrew W Roberts, John F Seymour, Mary Ann Anderson

Journal article  |  2020  |  Blood

Highly active BTK inhibitors (BTKis) and the BCL2 inhibitor venetoclax have transformed the therapeutic landscape for chronic lymp..

A predictive tool for early-stage CLL

Constantine S Tam, John F Seymour

Journal article  |  2020  |  Blood

The urgent need for integrated science to fight COVID-19 pandemic and beyond

Negar Moradian, Hans D Ochs, Constantine Sedikies, Michael R Hamblin, Carlos A Camargo, J Alfredo Martinez, Jacob D Biamonte, Mohammad Abdollahi, Pedro J Torres, Juan J Nieto, Shuji Ogino, John F Seymour, Ajith Abraham, Valentina Cauda, Sudhir Gupta, Seeram Ramakrishna, Frank W Sellke, Armin Sorooshian, A Wallace Hayes, Maria Martinez-Urbistondo, et al.

Journal article  |  2020  |  Journal of Translational Medicine

The COVID-19 pandemic has become the leading societal concern. The pandemic has shown that the public health concern is not only a..

Burden and clinical outcomes of hospital-coded infections in patients with cancer: an 11-year longitudinal cohort study at an Australian cancer centre

Jake C Valentine, Lisa Hall, Tim Spelman, Karin M Verspoor, John F Seymour, Danny Rischin, Karin A Thursky, Monica A Slavin, Leon J Worth

Journal article  |  2020  |  Supportive Care in Cancer

PURPOSE: Patients with cancer are at increased risk for infection, but the relative morbidity and mortality of all infections is n..

Durable Complete Remission and Long-Term Survival in FDG-PET Staged Patients with Stage III Follicular Lymphoma, Treated with Wide-Field Radiation Therapy

Michael P MacManus, Rodney J Hicks, Mathias Bressel, Belinda A Campbell, Andrew Wirth, Gail Ryan, H Miles Prince, Max Wolf, Rachel Brown, John F Seymour

Journal article  |  2020  |  Cancers

Advanced-stage follicular lymphoma (FL) is generally considered incurable with conventional systemic therapies, but historic serie..

Undetectable minimal residual disease should be the goal of venetoclax therapy in relapsed and refractory chronic lymphocytic leukaemia

Thomas Lew, Mary Ann Anderson, Victor Lin, Sasanka Handunnetti, Neil Came, David Westerman, Wall Meaghan, Constantine Tam, Andrew W Roberts, John F Seymour

Conference Proceedings  |  2020  |  LEUKEMIA & LYMPHOMA

Outcomes following the addition of rituximab to R/R CLL patients progressing after durable responses on venetoclax monotherapy

Sasanka Handunnetti, Mary Ann Anderson, Andrew W Roberts, Matthew Davids, Kathryn Humphrey, Brian Oliver, Abdullah Masud, Amanda Jacobson, John F Seymour

Conference Proceedings  |  2020  |  LEUKEMIA & LYMPHOMA

Time-limited venetoclax-rituximab (VenR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): first presentation of 4-year data from the MURANO study

John F Seymour, Thomas J Kipps, Barbara Eichhorst, Peter Hillmen, James D'Rozario, Sarit Assouline, Carolyn Owen, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Nicole Lamanna, Su Young Kim, Jenny Wu, Yanwen Jiang, Jue Wang, Marcus Lefebure, Michelle Boyer, Kathryn Humphrey, et al.

Conference Proceedings  |  2020  |  LEUKEMIA & LYMPHOMA

Abscopal Regressions of Lymphoma After Involved-Site Radiation Therapy Confirmed by Positron Emission Tomography.

Michael P MacManus, Michael S Hofman, Rodney J Hicks, Belinda A Campbell, Andrew Wirth, John F Seymour, Nicole Haynes, Kate Burbury

Journal article  |  2020  |  International Journal of Radiation Oncology*Biology*Physics

PURPOSE: Patients with abscopal regressions of lymphoma after palliative involved-site radiation therapy (ISRT), detected on seque..

Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on

Piers Blombery, Ella R Thompson, Nguyen Tamia, Richard W Birkinshaw, Jia-Nan Gong, Xiangting Chen, Michelle McBean, Rachel Thijssen, Thomas Conway, Mary Ann Anderson, John F Seymour, David A Westerman, Peter E Czabotar, David CS Huang, Andrew W Roberts

Journal article  |  2020  |  Blood

Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma

Thijs WH Flinsenberg, Charnelle C Tromedjo, Nan Hu, Ye Liu, Yin Guo, Kevin YT Thia, Tahereh Noori, Xiaomin Song, Han X Aw Yeang, Daniela G Tantalo, Sasanka Handunnetti, John F Seymour, Andrew W Roberts, David Ritchie, Rachel Koldej, Paul J Neeson, Lai Wang, Joseph A Trapani, Constantine S Tam, Ilia Voskoboinik

Journal article  |  2020  |  Haematologica

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months

Thomas E Lew, Mary Ann Anderson, Victor S Lin, Sasanka M Handunnetti, Neil A Came, Piers Blombery, David A Westerman, Meaghan Wall, Constantine S Tam, Andrew W Roberts, John F Seymour

Journal article  |  2020  |  Blood Advances

The highly selective BCL2 inhibitor venetoclax achieves deep responses in patients with relapsed or refractory (R/R) chronic lymph..

Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study

Rong Deng, Leonid Gibiansky, Tong Lu, Priya Agarwal, Hao Ding, Xiaobin Li, Smita Kshirsagar, Dan Lu, Chunze Li, Sandhya Girish, Jue Wang, Michelle Boyer, Kathryn Humphrey, Kevin J Freise, Ahmed Hamed Salem, John F Seymour, Arnon P Kater, Dale Miles

Journal article  |  2019  |  Clinical Pharmacokinetics

BACKGROUND: Venetoclax is a selective B-cell lymphoma-2 (BCL-2) inhibitor approved for use as monotherapy or with rituximab in pat..

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

Emmanuel Bachy, John F Seymour, Pierre Feugier, Fritz Offner, Armando Lopez-Guillermo, David Belada, Luc Xerri, John V Catalano, Pauline Brice, Francois Lemonnier, Alejandro Martin, Olivier Casasnovas, Lars M Pedersen, Veronique Dorvaux, David Simpson, Sirpa Leppa, Jean Gabarre, Maria G da Silva, Sylvie Glaisner, Loic Ysebaert, et al.

Journal article  |  2019  |  Journal of Clinical Oncology

PURPOSE: The PRIMA study (ClinicalTrials.gov identifier: NCT00140582) established that 2 years of rituximab maintenance after firs..

Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study

Rong Deng, Leonid Gibiansky, Tong Lu, Xiaobin Li, Dan Lu, Chunze Li, Sandhya Girish, Jue Wang, Michelle Boyer, Noopur Shankar, Kathryn Humphrey, Kevin J Freise, Ahmed Hamed Salem, John F Seymour, Arnon P Kater, Dale Miles

Journal article  |  2019  |  Leukemia & Lymphoma

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Constantine S Tam, Judith Trotman, Stephen Opat, Jan A Burger, Gavin Cull, David Gottlieb, Rosemary Harrup, Patrick B Johnston, Paula Marlton, Javier Munoz, John F Seymour, David Simpson, Alessandra Tedeschi, Rebecca Elstrom, Yiling Yu, Zhiyu Tang, Lynn Han, Jane Huang, William Novotny, Lai Wang, et al.

Journal article  |  2019  |  Blood

Zanubrutinib is a potent and highly selective inhibitor of Bruton tyrosine kinase (BTK). In this first-in-human, open--label, mult..

Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma

Piers Blombery, Richard W Birkinshaw, Tamia Nguyen, Jia-nan Gong, Ella R Thompson, Zhen Xu, David A Westerman, Peter E Czabotar, Michael Dickinson, David CS Huang, John F Seymour, Andrew W Roberts

Journal article  |  2019  |  British Journal of Haematology

A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma

Zi Yun Ng, Mark Bishton, David Ritchie, Robert Campbell, Michael Gilbertson, Kate Hill, Sumita Ratnasingam, Anthony Schwarer, Kate Manos, Sophie Shorten, Melissa Ng, Niles Nelson, Liu Xin, Sanjay De Mel Widanalage, Tenny Sunny, Duncan Purtill, Michelle Poon, Anna Johnston, Tara Cochrane, Hui-Peng Lee, et al.

Journal article  |  2019  |  Hematological Oncology

Mantle cell lymphoma (MCL) is an uncommon and typically aggressive form of lymphoma. Although often initially chemosensitive, rela..

Venetoclax, the First BCL-2 Inhibitor for Use in Patients With Chronic Lymphocytic Leukemia

John Seymour

Journal article  |  2019  |  Clinical advances in hematology & oncology : H&O

A Retrospective Evaluation of Risk of Peripartum Cardiac Dysfunction in Survivors of Childhood, Adolescent and Young Adult Malignancies

Lori Chait-Rubinek, Justin A Mariani, Natalie Goroncy, Alan Herschtal, Greg C Wheeler, Mary K Dwyer, John E Seymour, Belinda A Campbell

Journal article  |  2019  |  Cancers

Long-term survivors of childhood, adolescent and young adult (AYA) malignancies with past exposure to potentially cardiotoxic trea..

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

Andrew W Roberts, Shuo Ma, Thomas J Kipps, Steven E Coutre, Matthew S Davids, Barbara Eichhorst, Michael Hallek, John C Byrd, Kathryn Humphrey, Lang Zhou, Brenda Chyla, Jacqueline Nielsen, Jalaja Potluri, Su Young Kim, Maria Verdugo, Stephan Stilgenbauer, William G Wierda, John F Seymour

Journal article  |  2019  |  Blood

Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy

Candice Jamois, Ekaterina Gibiansky, Leonid Gibiansky, Vincent Buchheit, Denis Sahin, Guillaume Cartron, Robert Marcus, Wolfgang Hiddemann, John F Seymour, Jonathan C Strefford, Chantal E Hargreaves, Georgina Meneses-Lorente, Nicolas Frey, Guenter Fingerle-Rowson

Journal article  |  2019  |  British Journal of Clinical Pharmacology

Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations

Jacob D Soumerai, Ai Ni, Mohamed Darif, Anil Londhe, Guan Xing, Yong Mun, Neil E Kay, Tait D Shanafelt, Kari G Rabe, John C Byrd, Asher A Chanan-Khan, Richard R Furman, Peter Hillmen, Jeffrey Jones, John F Seymour, Jeffrey P Sharman, Lucille Ferrante, Mehrdad Mobasher, Thomas Stark, Vijay Reddy, et al.

Journal article  |  2019  |  The Lancet Haematology

High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia - lessons for immunopathogenesis and prescribing

Zaal Meher-Homji, Constantine S Tam, Jim Siderov, John Francis Seymour, Natasha E Holmes, Kyra YL Chua, Elizabeth J Phillips, Monica A Slavin, Jason A Trubiano

Journal article  |  2019  |  Leukemia & Lymphoma

The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment

Nicole Wong Doo, Victoria M White, Kara Martin, Julie K Bassett, H Miles Prince, Simon J Harrison, Michael Jefford, Ingrid Winship, Jeremy L Millar, Roger L Milne, John F Seymour, Graham G Giles

Journal article  |  2019  |  Cancers

INTRODUCTION: Diffuse large B cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma for which a cure is usually the ..

Incident Chronic Kidney Disease After Radical Nephrectomy for Renal Cell Carcinoma

Robert J Ellis, Victoria M White, Damien M Bolton, Michael D Coory, Ian D Davis, Ross S Francis, Graham G Giles, Glenda C Gobe, David JT Marco, Rachel E Neale, Simon T Wood, Susan J Jordan, Graham Giles, Victoria White, Michael Coory, Jeremy Millar, Damien Bolton, Ian Davis, Ingrid Winship, Ian Roos, et al.

Journal article  |  2019  |  Clinical Genitourinary Cancer

Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression

John F Seymour, Robert Marcus, Andrew Davies, Eve Gallop-Evans, Andrew Grigg, Andrew Haynes, Michael Herold, Thomas Illmer, Herman Nilsson-Ehle, Martin Soekler, Ulrich Duenzinger, Tina Nielsen, Aino Launonen, Wolfgang Hiddemann

Journal article  |  2019  |  Haematologica

Better Sepsis Management Rather Than Fluoroquinolone Prophylaxis for Patients With Cancer-Related Immunosuppression

Monica A Slavin, Leon J Worth, John F Seymour, Karin A Thursky

Journal article  |  2019  |  Journal of Clinical Oncology

The trials and tribulations of conducting an m-health pilot randomized controlled trial to improve oral cancer therapy adherence: recommendations for future multisite, non-drug clinical trials

Lahiru Russell, Michaela C Pascoe, John F Seymour, Sanchia Aranda, Phyllis Butow, Karla Gough, Penelope Schofield

Journal article  |  2019  |  BMC Research Notes

OBJECTIVE: Integrating mobile phone-based health (m-health) interventions into healthcare systems is one solution to improve acces..

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia

Melita Kenealy, Mark Hertzberg, Warwick Benson, Kerry Taylor, Ilona Cunningham, Will Stevenson, Devendra Hiwase, Richard Eek, Daniela Zantomio, Steve Jong, Meaghan Wall, Piers Blombery, Tracey Gerber, Marlyse Debrincat, Diana Zannino, John F Seymour

Journal article  |  2019  |  Haematologica

A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma

Greg Hapgood, Janey M Stone, Diana Zannino, Anup George, Paula Marlton, Henry Miles Prince, Chi-Hung Hui, Ian Prosser, Ian D Lewis, Kenneth Bradstock, John F Seymour

Journal article  |  2019  |  Leukemia & Lymphoma

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Piers Blombery, Mary Ann Anderson, Jia-nan Gong, Rachel Thijssen, Richard W Birkinshaw, Ella R Thompson, Charis E Teh, Tamia Nguyen, Zhen Xu, Christoffer Flensburg, Thomas E Lew, Ian J Majewski, Daniel HD Gray, David A Westerman, Constantine S Tam, John F Seymour, Peter E Czabotar, David CS Huang, Andrew W Roberts

Journal article  |  2019  |  Cancer Discovery

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

Arnon P Kater, John F Seymour, Peter Hillmen, Barbara Eichhorst, Anton W Langerak, Carolyn Owen, Maria Verdugo, Jenny Wu, Elizabeth A Punnoose, Yanwen Jiang, Jue Wang, Michelle Boyer, Kathryn Humphrey, Mehrdad Mobasher, Thomas J Kipps

Journal article  |  2019  |  Journal of Clinical Oncology

Further Examining the TROG 99.03 Trial in Early-Stage Follicular Lymphoma: Cure Rate and the Role of Positron Emission Tomography Reply

Michael MacManus, Richard Fisher, Bev McClure, John F Seymour

Journal article  |  2019  |  Journal of Clinical Oncology

Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma

Rishu Agarwal, Yih-Chih Chan, Constantine S Tam, Tane Hunter, Dane Vassiliadis, Charis E Teh, Rachel Thijssen, Paul Yeh, Stephen Q Wong, Sarah Ftouni, Enid YN Lam, Mary Ann Anderson, Christiane Pott, Omer Gilan, Charles C Bell, Kathy Knezevic, Piers Blombery, Kathleen Rayeroux, Adrian Zordan, Jason Li, et al.

Journal article  |  2019  |  Nature Medicine

Outcome of patients with early-stage follicular lymphoma staged with F-18-Fluorodeoxyglucose (FDG) positron emission tomography (PET) and treated with radiotherapy alone

Sweet Ping Ng, Richard Khor, Mathias Bressel, Michael MacManus, John F Seymour, Rodney J Hicks, Andrew Wirth

Journal article  |  2019  |  European Journal of Nuclear Medicine and Molecular Imaging

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma

Matthew S Davids, Gottfried von Keudell, Craig A Portell, Jonathon B Cohen, David C Fisher, Francine Foss, Andrew W Roberts, John F Seymour, Rod A Humerickhouse, Constantine S Tam

Journal article  |  2018  |  Journal of Clinical Oncology

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

Hartmut Doehner, Anna Dolnik, Lin Tang, John F Seymour, Mark D Minden, Richard M Stone, Teresa Bernal del Castillo, Haifa Kathrin Al-Ali, Valeria Santini, Paresh Vyas, CL Beach, Kyle J MacBeth, Barry S Skikne, Steve Songer, Nora Tu, Lars Bullinger, Herve Dombret

Journal article  |  2018  |  Leukemia

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells

David M Ross, Ilaria S Pagani, Naranie Shanmuganathan, Chung H Kok, John F Seymour, Anthony K Mills, Robin J Filshie, Christopher K Arthur, Dang Phuong, Verity A Saunders, Jodi Braley, Agnes S Yong, David T Yeung, Deborah L White, Andrew P Grigg, Anthony P Schwarer, Susan Branford, Timothy P Hughes

Journal article  |  2018  |  Leukemia

Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia

William G Wierda, Andrew W Roberts, Paolo Ghia, Jennifer R Brown, Stephan Stilgenbauer, Florence Cymbalista, Nicole Lamanna, John F Seymour, Sebastian Boettcher, Madlaina Breuleux, Brenda Chyla, Lang Zhou, Jacqueline Nielsen, Su Young Kim, Jalaja Potluri, Johnathan C Maher, Peter Hillmen

Conference Proceedings  |  2018  |  Blood

Serial Minimal Residual Disease Evaluation in Patients with Chronic Lymphocytic Leukemia Under Long-Term Venetoclax Treatment

Thomas Lew, Mary Ann Anderson, Constantine S Tam, Sasanka Handunnetti, Dennis Carney, Max Wolf, Surender Juneja, David Alan Westerman, Andrew W Roberts, John F Seymour

Conference Proceedings  |  2018  |  Blood

First Prospective Data on Impact of Minimal Residual Disease on Long - Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study

Arnon P Kater, Peter Hillmen, Barbara Eichhorst, Anton W Langerak, Thomas J Kipps, Carolyn Owen, Michelle Boyer, Kathryn Humphrey, Elizabeth A Punnoose, Jue Wang, Brenda Chyla, Maria E Verdugo, Jenny Wu, Yanwen Jiang, Mehrdad Mobasher, John F Seymour

Conference Proceedings  |  2018  |  Blood

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmuniotheraphy

Jacob D Soumerai, Ai Ni, Mohamed Darif, Anil Londhe, Guan Xing, Yong Mun, Neil E Kay, Tait D Shanafelt, Kari G Chaffee, Richard R Furman, Peter Hillmen, Jeff Sharman, John F Seymour, Asher A Chanan-Khan, John C Byrd, Jeffrey A Jones, Lucille A Ferrante, Lyndah K Dreiling, Mehrdad Mobasher, Thomas Stark, et al.

Conference Proceedings  |  2018  |  Blood

A Novel Prognostic Model That Is Superior to FLIPI-1 and FLIPI-2 and Integrated Clinical and Treatments Factors to Predict Progression-Free Survival and Early Treatment Failure in Patients with Follicular Lymphoma in the GALLIUM Trial

Farheen Mir, Andrew Grigg, Michael Herold, Wolfgang Hiddemann, Robert Marcus, John F Seymour, Christopher R Bolen, Andrea Knapp, Aino Launonen, Federico Mattiello, Tina Nielsen, Mikkel Z Oestergaard, Michael Wenger, Carla Casulo

Conference Proceedings  |  2018  |  Blood

MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

John F Seymour, Thomas J Kipps, Barbara Eichhorst, Peter Hillmen, James D'Rozario, Sarit Assouline, Carolyn Owen, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Nicole Lamanna, Maria E Verdugo, Elizabeth A Punnoose, Yanwen Jiang, Jue Wang, Michelle Boyer, Kathryn Humphrey, Mehrdad Mobasher, et al.

Conference Proceedings  |  2018  |  Blood

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Piers Blombery, Mary Ann Anderson, Jianan Gong, Rachel Thijssen, Richard W Birkinshaw, Ella Thompson, Charis E Teh, Tamia Nguyen, Zhen Xu, Christoffer Flensburg, Thomas Lew, Ian Majewski, Daniel Gray, David Alan Westerman, Constantine S Tam, John F Seymour, Peter E Czabotar, David Huang, Andrew W Roberts

Conference Proceedings  |  2018  |  Blood

Durability of Responses on Continuous Therapy and Following Drug Cessation in Deep Responders with Venetoclax and Rituximab

Danielle M Brander, John F Seymour, Shuo Ma, Mary Ann Anderson, Michael Y Choi, Thomas J Kipps, Kathryn Humphrey, Abdullah Masud, Ruby Nandam, Su Young Kim, Maria E Verdugo, Andrew W Roberts

Conference Proceedings  |  2018  |  Blood

Long-Term Follow-up of Patients with Mantle Cell Lymphoma Treated with Venetoclax Monotherapy

Matthew S Davids, Andrew W Roberts, William G Wierda, Kathryn Humphrey, Debbie J Alter, Abdullah Masud, Eike C Buss, Maria E Verdugo, John F Seymour

Conference Proceedings  |  2018  |  Blood

Teriparatide improves healing of medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial

Ie-Wen Sim, Gelsomina Borromeo, John Seymour, Peter Ebeling

Conference Proceedings  |  2018  |  JOURNAL OF BONE AND MINERAL RESEARCH

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies

Gita Thanarajasingam, Lori M Minasian, Frederic Baron, Franco Cavalli, R Angelo De Claro, Amylou C Dueck, Tarec El-Galaly, Neil Everest, Jan Geissler, Christian Gisselbrecht, John Gribben, Mary Horowitz, S Percy Ivy, Caron A Jacobson, Armand Keating, Paul G Kluetz, Aviva Krauss, Yok Lam Kwong, Richard F Little, Francois-Xavier Mahon, et al.

Journal article  |  2018  |  The Lancet Haematology

Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03

Michael MacManus, Richard Fisher, Daniel Roos, Peter O'Brien, Andrew Macann, Sidney Davis, Richard Tsang, David Christie, Bev McClure, David Joseph, Jayasingham Jayamohan, John F Seymour

Journal article  |  2018  |  Journal of Clinical Oncology

"Reversible" myelodysplastic syndrome or ineffectual clonal haematopoiesis? - add(6p) myeloid neoplasm with a spontaneous cytogenetic remission

K Rady, P Blombery, DA Westerman, M Wall, M Curtis, LJ Campbell, JF Seymour

Journal article  |  2018  |  Leukemia Research

Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Matthew S Davids, Michael Hallek, William Wierda, Andrew W Roberts, Stephan Stilgenbauer, Jeffrey A Jones, John F Gerecitano, Su Young Kim, Jalaja Potluri, Todd Busman, Andrea Best, Maria E Verdugo, Elisa Cerri, Monali Desai, Peter Hillmen, John F Seymour

Journal article  |  2018  |  Clinical Cancer Research

Management of Pregnancy in Women With Chronic Myeloid Leukemia

David M Ross, Kate L Burbury, Andrew P Grigg, Timothy P Hughes, John F Seymour

Journal article  |  2018  |  Journal of Clinical Oncology

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL)

Qian Shi, Norbert Schmitz, Fang-Shu Ou, Jesse G Dixon, David Cunningham, Michael Pfreundschuh, John F Seymour, Ulrich Jaeger, Thomas M Habermann, Corinne Haioun, Herve Tilly, Herve Ghesquieres, Francesco Merli, Marita Ziepert, Raoul Herbrecht, Jocelyne Flament, Tommy Fu, Bertrand Coiffier, Christopher R Flowers

Journal article  |  2018  |  Journal of Clinical Oncology

Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies

Ing S Tiong, John Reynolds, Kenneth F Bradstock, John F Seymour, Andrew H Wei

Journal article  |  2018  |  Blood Cancer Journal

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety

Wolfgang Hiddemann, Anna Maria Barbui, Miguel A Canales, Paul K Cannell, Graham P Collins, Jan Duerig, Roswitha Forstpointner, Michael Herold, Mark Hertzberg, Magdalena Klanova, John Radford, John F Seymour, Kensei Tobinai, Judith Trotman, Alis Burciu, Gunter Fingerle-Rowson, Marcel Wolbers, Tina Nielsen, Robert E Marcus

Journal article  |  2018  |  Journal of Clinical Oncology

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

MJ Maurer, TM Habermann, Q Shi, N Schmitz, D Cunningham, M Pfreundschuh, JF Seymour, U Jaeger, C Haioun, H Tilly, H Ghesquieres, F Merli, M Ziepert, R Herbrecht, J Flament, T Fu, CR Flowers, B Coiffier

Journal article  |  2018  |  Annals of Oncology

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy

Emmanuel Bachy, Matthew J Maurer, Thomas M Habermann, Benedicte Gelas-Dore, Delphine Maucort-Boulch, Jane A Estell, Eric Van den Neste, Reda Bouabdallah, Emmanuel Gyan, Andrew L Feldman, Joan Bargay, Alain Delmer, Susan L Slager, Maria Gomes da Silva, Olivier Fitoussi, David Belada, Herve Maisonneuve, Tanin Intragumtornchai, Stephen M Ansell, Thierry Lamy, et al.

Journal article  |  2018  |  Blood

Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas

Anastasios Stathis, Alexia Iasonos, John F Seymour, Catherine Thieblemont, Vincent Ribrag, Emanuele Zucca, Anas Younes

Journal article  |  2018  |  Clinical Cancer Research

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial

Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Peter Hillmen, John F Seymour, Steven Coutre, Wojciech Jurczak, Stephen P Mulligan, Anna Schuh, Sarit Assouline, Clemens-Martin Wendtner, Andrew W Roberts, Matthew S Davids, Johannes Bloehdorn, Talha Munir, Sebastian Boettcher, Lang Zhou, Ahmed Hamed Salem, Monali Desai, Brenda Chyla, et al.

Journal article  |  2018  |  Journal of Clinical Oncology

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Michael Hallek, Bruce D Cheson, Daniel Catovsky, Federico Caligaris-Cappio, Guillermo Dighiero, Hartmut Doehner, Peter Hillmen, Michael Keating, Emili Montserrat, Nicholas Chiorazzi, Stephan Stilgenbauer, Kanti R Rai, John C Byrd, Barbara Eichhorst, Susan O'Brien, Tadeusz Robak, John F Seymour, Thomas J Kipps

Journal article  |  2018  |  Blood

JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias

Sang-Kyu Kim, Deborah A Knight, Lisa R Jones, Stephin Vervoort, Ashley P Ng, John F Seymour, James E Bradner, Michaela Waibel, Lev Kats, Ricky W Johnstone

Journal article  |  2018  |  Genes and Develpment

Venetoclax-Rituximab in Chronic Lymphocytic Leukemia

Mehmet S Copur, Dron Gauchan, David Crockett

Journal article  |  2018  |  New England Journal of Medicine

High, durable minimal residual disease negativity (MRD-) with venetoclax plus rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.

Peter Hillmen, Arnon P Kater, John Francis Seymour, Anton W Langerak, Barbara Eichhorst, Carolyn Owen, Sarit E Assouline, Ann Janssens, Paula Marlton, Xavier C Badoux, Rogier Mous, Brenda Chyla, Rod Humerickhouse, Michelle Boyer, Kathryn Humphrey, Yanwen Jiang, Elizabeth Punnoose, Jue Wang, Qun Jenny Wu, Mehrdad Mobasher

Conference Proceedings  |  2018  |  Journal of Clinical Oncology

Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL.

Matthew Steven Davids, John Francis Seymour, Andrew Warwick Roberts, Barbara Eichhorst, Thomas J Kipps, Anthony R Mato, Stephan Stilgenbauer, Mehrdad Mobasher, Monali Bhardwaj Desai, Jalaja Potluri, German E Pena, Maria E Verdugo, Jacqueline Nielsen, Aimee Cyr, Leanne Lash Fleming, Michael J Hallek

Conference Proceedings  |  2018  |  Journal of Clinical Oncology

Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma

Tarec Christoffer El-Galaly, Chan Yoon Cheah, Mette Dahl Bendtsen, Grzegorz S Nowakowski, Roopesh Kansara, Kerry J Savage, Joseph M Connors, Laurie H Sehn, Neta Goldschmidt, Adir Shaulov, Umar Farooq, Brian K Link, Andres JM Ferreri, Teresa Calimeri, Caterina Cecchetti, Eldad J Dann, Carrie A Thompson, Tsofia Inbar, Matthew J Maurer, Inger Lise Gade, et al.

Journal article  |  2018  |  European Journal of Cancer

Safety and Efficacy of Venetoclax (VEN) in Combination With Decitabine or Azacitidine in Treatment-Naive, Elderly Patients (>= 65 Years) With Acute Myeloid Leukemia (AML)

K Pratz, D Pollyea, B Jonas, V Pullarkat, A Wei, M Arellano, P Becker, O Frankfurt, M Thirman, A Pigneux, C Recher, J Seymour, N Dvorak, T Xu, R Humerickhouse, M Mabry, J Potluri, A Letai, C DiNardo

Conference Proceedings  |  2018  |  BRITISH JOURNAL OF HAEMATOLOGY

Venetoclax (VEN) in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL).

M Davids, A Roberts, J Seymour, W Wierda, S Puvvada, L Gressick, D Alter, L Zhou, S Kim, M Verdugo, J Gerecitano

Conference Proceedings  |  2018  |  BRITISH JOURNAL OF HAEMATOLOGY

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

Constantine S Tam, Mary Ann Anderson, Christiane Pott, Rishu Agarwal, Sasanka Handunnetti, Rodney J Hicks, Kate Burbury, Gillian Turner, Juliana Di Iulio, Mathias Bressel, David Westerman, Stephen Lade, Martin Dreyling, Sarah-Jane Dawson, Mark A Dawson, John F Seymour, Andrew W Roberts

Journal article  |  2018  |  New England Journal of Medicine

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

JF Seymour, TJ Kipps, B Eichhorst, P Hillmen, J D'Rozario, S Assouline, C Owen, J Gerecitano, T Robak, J De la Serna, U Jaeger, G Cartron, M Montillo, R Humerickhouse, EA Punnoose, Y Li, M Boyer, K Humphrey, M Mobasher, AP Kater

Journal article  |  2018  |  New England Journal of Medicine

Patient perceptions of treatment-free remission in chronic myeloid leukemia

Lucia A Villemagne Sanchez, Clare O'Callaghan, Karla Gough, Karen Hall, Yoshihisa Kashima, John F Seymour, Penelope Schofield, David M Ross

Journal article  |  2018  |  Leukemia & Lymphoma

Comprehensive genomic characterization dissects the complex biology of a case of synchronous Burkitt lymphoma and myeloid malignancy with shared hematopoietic ancestry

Georgina L Ryland, Kate Jones, Michelle McBean, Amit Khot, John Francis Seymour, Piers Blombery

Journal article  |  2018  |  Leukemia & Lymphoma

Obinutuzumab Treatment of Follicular Lymphoma REPLY

Robert Marcus, John F Seymour, Wolfgang Hiddemann

Journal article  |  2017  |  New England Journal of Medicine

The authors reply

R Marcus, JF Seymour, W Hiddemann

Journal article  |  2017  |  New England Journal of Medicine

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

John F Seymour, Hartmut Doehner, Aleksandra Butrym, Agnieszka Wierzbowska, Dominik Selleslag, Jun Ho Jang, Rajat Kumar, James Cavenagh, Andre C Schuh, Anna Candoni, Christian Recher, Irwindeep Sandhu, Teresa Bernal del Castillo, Haifa Kathrin Al-Ali, Jose Falantes, Richard M Stone, Mark D Minden, Jerry Weaver, Steve Songer, CL Beach, et al.

Journal article  |  2017  |  BMC Cancer

Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia

Courtney D DiNardo, Daniel A Pollyea, Brian A Jonas, Marina Konopleva, Vinod Pullarkat, Andrew Wei, Hagop M Kantarjian, Arnaud Pigneux, Christian Recher, John F Seymour, Martin Dunbar, Tu Xu, Mack Mabry, Jalaja Potluri, Keith Pratz, Anthony Letai

Conference Proceedings  |  2017  |  BLOOD

An International Multicenter Retrospective Comparison of Induction Chemoimmunotherapy Regimens on Outcomes in Patients with Transplant-Eligible Mantle Cell Lymphoma

Zi Yun Ng, Mark Bishton, David Ritchie, Robert Campbell, Michael P Gilbertson, Kate Hill, Sumita Ratnasingam, Anthony P Schwarer, Kate Manos, Sophie Shorten, Melissa Liet Hing Ng, Niles Elizabeth Nelson, Liu Xin, Sanjay De Mel, Tenny Sunny, Duncan Purtill, Michelle Poon, Anna M Johnston, Tara Cochrane, Hui-Peng Lee, et al.

Conference Proceedings  |  2017  |  BLOOD

Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study

John F Seymour, Thomas J Kipps, Barbara F Eichhorst, Peter Hillmen, James M D'Rozario, Sarit Assouline, Carolyn Jane Owen, John Gerecitano, Tadeusz Robak, Javier De la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Rod Humerickhouse, Elizabeth Punnoose, Yan Li, Michelle Boyer, Kathryn Humphrey, Mehrdad Mobasher, Arnon P Kater

Conference Proceedings  |  2017  |  BLOOD

Impact of Number of Prior Therapies and Bulk of Disease on Outcomes with Venetoclax (VEN) Monotherapy for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

William G Wierda, John F Seymour, Andrew W Roberts, Su Young Kim, Leanne Lash-Fleming, Johnathan Maher, Todd Busman, Lang Zhou, Jacqueline Nielsenand Stephan Stilgenbauer

Conference Proceedings  |  2017  |  BLOOD

Discovery and Validation of a Simplified Scoring System (the PRIMA-Prognostic Index) in De NovoFollicular Lymphoma Treated Initially with Immunochemotherapy

Emmanuel Bachy, Matthew J Maurer, Thomas M Habermann, Benedicte Gelas Dore, Delphine Maucort-Boulch, Jane Estell, E Van den Este, Reda Bouabdallah, Andrew L Feldman, Joan Bargay, Alain Jacques Delmer, Susan L Slager, Maria Gomes Silva, Olivier Fitoussi, David Belada, Herve Maisonneuve, Tanin Intragumtornchai, Stephen M Ansell, Thierry Lamy, Peggy Dartigues-Cuilleres, et al.

Conference Proceedings  |  2017  |  BLOOD

Long Term Follow-up of the PRIMA Study: Half of Patients Receiving Rituximab Maintenance Remain Progression Free at 10 Years

Gilles Andre Salles, John Francis Seymour, Pierre Feugier, Fritz Offner, Armando Lopez-Guillermo, David Belada, Luc Xerri, Reda Bouabdallah, John Catalano, Pauline Brice, Corinne Haioun, Alejandro Martin, Lars Moller Pedersen, Alain Jacques Delmer, David Simpson, Sirpa Leppa, Pierre Soubeyran, Rene-Olivier Casasnovas, Tanin Intragumtornchai, Vincent Ribrag, et al.

Conference Proceedings  |  2017  |  BLOOD

Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML)

David M Ross, Ilaria S Pagani, Naranie Shanmuganathan, John F Seymour, Anthony K Mills, Robin J Filshie, Christopher K Arthur, Dang Phuong, Verity A Saunders, Jody Braley, David T Yeung, Deborah L White, Andrew P Grigg, Anthony P Schwarer, Susan Branford, Timothy P Hughes

Conference Proceedings  |  2017  |  BLOOD

Influence of Baseline Disease Characteristics and Exposure to Obinutuzumab on Clinical Outcome in Patients with Previously Untreated Advanced Follicular Lymphoma Treated with Obinutuzumab-Based Immunochemotherapy in the GALLIUM Trial

Candice Jamois, Ekaterina Gibiansky, Leonid Gibiansky, Vincent Buchheit, Pauline Baumlin, Denis Sahin, Guillaume Cartron, Robert Marcus, Wolfgang Hiddemann, John F Seymour, Jonathan C Strefford, Georgina Meneses-Lorente, Nicolas Frey, Gunter Fingerle-Rowson

Conference Proceedings  |  2017  |  BLOOD

Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015

Randy D Gascoyne, Bertrand Nadel, Laura Pasqualucci, Jude Fitzgibbon, Jacqueline E Payton, Ari Melnick, Oliver Weigert, Karin Tarte, John G Gribben, Jonathan W Friedberg, John F Seymour, Franco Cavalli, Emanuele Zucca

Journal article  |  2017  |  Hematological Oncology

Mobile Health Intervention to Increase Oral Cancer Therapy Adherence in Patients With Chronic Myeloid Leukemia (The REMIND System): Clinical Feasibility and Acceptability Assessment

Amanda Pereira-Salgado, Jennifer A Westwood, Lahiru Russell, Anna Ugalde, Bronwen Ortlepp, John F Seymour, Phyllis Butow, Lawrence Cavedon, Kevin Ong, Sanchia Aranda, Sibilah Breen, Suzanne Kirsa, Andrew Dunlevie, Penelope Schofield

Journal article  |  2017  |  JMIR mHealth and uHealth

The influence of unmet supportive care needs on anxiety and depression during cancer treatment and beyond: a longitudinal study of survivors of haematological cancers

Devesh Oberoi, Victoria M White, John F Seymour, H Miles Prince, Simon Harrison, Michael Jefford, Ingrid Winship, David Hill, Damien Bolton, Anne Kay, Jeremy Millar, Nicole Wong Doo, Graham Giles

Journal article  |  2017  |  Supportive Care in Cancer

Distress and unmet needs during treatment and quality of life in early cancer survivorship: A longitudinal study of haematological cancer patients

Devesh V Oberoi, Victoria M White, John F Seymour, H Miles Prince, Simon Harrison, Michael Jefford, Ingrid Winship, David J Hill, Damien Bolton, Jeremy Millar, Nicole Wong Doo, Anne Kay, Graham Giles

Journal article  |  2017  |  European Journal of Haematology

EFFICACY AND SAFETY OF AZACITIDINE (AZA) VERSUS CONVENTIONAL TREATMENT (TC) IN PATIENTS=75 YEARS WITH ACUTE MYELOBLASTIC LEUKEMIA (AML) IN THE PHASE III STUDY AZA AML001

J Bargay Lleonart, JF Seymour, R Buckstein, V Santini, H Doehner, RM Stone, MD Minden, Kuo Y Ching, D Ben Yehuda, S Songer, J Weaver, CL Beach, H Dombret

Conference Proceedings  |  2017  |  HAEMATOLOGICA

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

R Marcus, A Davies, K Ando, W Klapper, S Opat, C Owen, E Phillips, R Sangha, R Schlag, JF Seymour, W Townsend, M Trneny, M Wenger, G Fingerle-Rowson, K Rufibach, T Moore, M Herold, W Hiddemann

Journal article  |  2017  |  New England Journal of Medicine

High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma

Chan Yoon Cheah, David Joske, Gavin Cull, Michael Gilbertson, Stephen S Opat, Constantine S Tam, Andrew Wirth, John F Seymour

Journal article  |  2017  |  British Journal of Haematology

Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era

LA Butler, CS Tam, JF Seymour

Journal article  |  2017  |  Blood Reviews

Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia

Andrew W Roberts, Stephan Stilgenbauer, John F Seymour, David CS Huang

Journal article  |  2017  |  Clinical Cancer Research

Azacitidine in adult patients with acute myeloid leukemia

Andre C Schuh, Hartmut Doehner, Lisa Pleyer, John F Seymour, Pierre Fenaux, Herve Dombret

Journal article  |  2017  |  Critical Reviews in Oncology/Hematology

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

A Younes, P Hilden, B Coiffier, A Hagenbeek, G Salles, W Wilson, JF Seymour, K Kelly, J Gribben, M Pfreunschuh, F Morschhauser, H Schoder, AD Zelenetz, J Rademaker, R Advani, N Valente, C Fortpied, TE Witzig, LH Sehn, A Engert, et al.

Journal article  |  2017  |  Annals of Oncology

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax

Mary Ann Anderson, Constantine Tam, Thomas E Lew, Surender Juneja, Manu Juneja, David Westerman, Meaghan Wall, Stephen Lade, Alexandra Gorelik, David CS Huang, John F Seymour, Andrew W Roberts

Journal article  |  2017  |  Blood

Primary Breast Lymphoma-Population-Level Insights into an Infrequent but Increasingly Recognized Subtype of Lymphoma

Piers Blombery, Henry M Prince, John F Seymour

Journal article  |  2017  |  JNCI: Journal of the National Cancer Institute

The landscape of new drugs in lymphoma

Anas Younes, Stephen Ansell, Nathan Fowler, Wyndham Wilson, Sven de Vos, John Seymour, Ranjana Advani, Andres Forero, Franck Morschhauser, Marie Jose Kersten, Kensei Tobinai, Pier Luigi Zinzani, Emanuele Zucca, Jeremy Abramson, Julie Vose

Journal article  |  2017  |  Nature Reviews Clinical Oncology

The course of anxiety, depression and unmet needs in survivors of diffuse large B cell lymphoma and multiple myeloma in the early survivorship period

Devesh Oberoi, Victoria White, John Seymour, H Miles Prince, Simon Harrison, Michael Jefford, Ingrid Winship, David Hill, Damien Bolton, Anne Kay, Jeremy Millar, Nicole Wong Doo, Graham Giles

Journal article  |  2017  |  Journal of Cancer Survivorship

Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia

John F Seymour, Hartmut Doehner, Mark D Minden, Richard Stone, Dominique Gambini, Donna Dougherty, CL Beach, Jerry Weaver, Herve Dombret

Journal article  |  2017  |  Leukemia & Lymphoma

Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia

Kenneth F Bradstock, Emma Link, Juliana Di Iulio, Jeff Szer, Paula Marlton, Andrew H Wei, Arno Enno, Anthony Schwarer, Ian D Lewis, James D'Rozario, Luke Coyle, Gavin Cull, Phillip Campbell, Michael F Leahy, Uwe Hahn, Paul Cannell, Campbell Tiley, Ray M Lowenthal, John Moore, Kimberly Cartwright, et al.

Journal article  |  2017  |  Journal of Clinical Oncology

Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): Primary endpoint assessment of the phase 2 AIM study.

Constantine Si Lun Tam, Andrew Warwick Roberts, Mary Ann Anderson, Sarah-Jane Dawson, Rodney J Hicks, Kate Burbury, Gillian Turner, Juliana Di Iulio, Mathias Bressel, David A Westerman, Rishu Agarwal, Christiane Pott, Martin H Dreyling, Mark A Dawson, John Francis Seymour

Conference Proceedings  |  2017  |  Journal of Clinical Oncology

Relationship of bone marrow blast (BMBL) response to overall survival (OS) in a multicenter study of rigosertib (Rigo) in patients (pts) with myelodysplastic syndrome (MDS) with excess blasts progressing on or after treatment with a hypomethylating agent (HMA)

Aref Al-Kali, Devendra Hiwase, Maria R Baer, Peter Greenberg, Jake Shortt, Robert Collins, David P Steensma, Amit Verma, Gail J Roboz, Jamile M Shammo, Oliver G Ottmann, John Francis Seymour, Jeffrey Szer, Wolfgang Meyer, Patrick Simon Zbyszewski, Michael E Petrone, Steven M Fruchtman, Guillermo Garcia-Manero, Lewis R Silverman

Conference Proceedings  |  2017  |  Journal of Clinical Oncology

Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?

CS Tam, JF Seymour

Journal article  |  2017  |  Annals of Oncology

Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors

Kah-Lok Chan, Piers Blombery, Kate Jones, Stephen Lade, Dennis Carney, Huy Tran, John F Seymour, Constantine S Tam

Journal article  |  2017  |  British Journal of Haematology

The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy

Tarec Christoffer El-Galaly, Diego Villa, Thomas Yssing Michaelsen, Martin Hutchings, Nabegh George Mikhaeel, Kerry J Savage, Laurie H Sehn, Sally Barrington, Jakob W Hansen, Daniel Smith, Kirsty Rady, Karen J Mylam, Thomas S Larsen, Staffan Holmberg, Maja B Juul, Sabrina Cordua, Michael R Clausen, Kristina B Jensen, Hans E Johnsen, John F Seymour, et al.

Journal article  |  2017  |  European Journal of Cancer

Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia

Paul Yeh, Tane Hunter, Devbarna Sinha, Sarah Ftouni, Elise Wallach, Damian Jiang, Yih-Chih Chan, Stephen Q Wong, Maria Joao Silva, Ravikiran Vedururu, Kenneth Doig, Enid Lam, Gisela Mir Arnau, Timothy Semple, Meaghan Wall, Andjelija Zivanovic, Rishu Agarwal, Pasquale Petrone, Kate Jones, David Westerman, et al.

Journal article  |  2017  |  Nature Communications

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Matthew S Davids, Andrew W Roberts, John F Seymour, John M Pagel, Brad S Kahl, William G Wierda, Soham Puvvada, Thomas J Kipps, Mary Ann Anderson, Ahmed Hamed Salem, Martin Dunbar, Ming Zhu, Franklin Peale, Jeremy A Ross, Lori Gressick, Monali Desai, Su Young Kim, Maria Verdugo, Rod A Humerickhouse, Gary B Gordon, et al.

Journal article  |  2017  |  Journal of Clinical Oncology

Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia

Constantine S Tam, Thomas Kimber, John F Seymour

Journal article  |  2017  |  British Journal of Haematology

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Michael R Grever, Omar Abdel-Wahab, Leslie A Andritsos, Versha Banerji, Jacqueline Barrientos, James S Blachly, Timothy G Call, Daniel Catovsky, Claire Dearden, Judit Demeter, Monica Else, Francesco Forconi, Alessandro Gozzetti, Anthony D Ho, James B Johnston, Jeffrey Jones, Gunnar Juliusson, Eric Kraut, Robert J Kreitman, Loree Larratt, et al.

Journal article  |  2017  |  Blood

Early Treatment Intensification With R-ICE And 90Y-Ibritumomab Tiuxetan (Zevalin)-BEAM Stem Cell Transplantation In Patients With High Risk Diffuse Large B-Cell Lymphoma Patients And Positive Interim PET After 4 Cycles Of R-CHOP-14

Mark Hertzberg, Maher K Gandhi, Judith Trotman, Belinda Butcher, John Taper, Amanda Johnston, Devinder Gill, Shir-Jing Ho, Gavin Cull, Keith Fay, Geoff Chong, Andrew Grigg, Ian D Lewis, Sam Milliken, William Renwick, Uwe Hahn, Robin Filshie, George Kannourakis, Anne-Marie Watson, Pauline Warburton, et al.

Journal article  |  2017  |  Haematologica

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

John F Seymour, Shuo Ma, Danielle M Brander, Michael Y Choi, Jacqueline Barrientos, Matthew S Davids, Mary Ann Anderson, Anne W Beaven, Steven T Rosen, Constantine S Tam, Betty Prine, Suresh K Agarwal, Wijith Munasinghe, Ming Zhu, L Leanne Lash, Monali Desai, Elisa Cerri, Maria Verdugo, Su Young Kim, Rod A Humerickhouse, et al.

Journal article  |  2017  |  The Lancet Oncology

Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML)

Melita Kenealy, Nigel Patton, Robin Filshie, Andrew Nicol, Shir-Jing Ho, Mark Hertzberg, Tony Mills, Ian Prosser, Emma Link, Linda Cowan, Diana Zannino, John F Seymour

Journal article  |  2017  |  Leukemia & Lymphoma

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

Lisa Pleyer, Hartmut Doehner, Herve Dombret, John F Seymour, Andre C Schuh, CL Beach, Arlene S Swern, Sonja Burgstaller, Reinhard Stauder, Michael Girschikofsky, Heinz Sill, Konstantin Schlick, Josef Thaler, Britta Halter, Sigrid Machherndl Spandl, Armin Zebisch, Angelika Pichler, Michael Pfeilstoecker, Eva M Autzinger, Alois Lang, et al.

Journal article  |  2017  |  International Journal of Molecular Sciences

Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib

Khai Li Chai, Gail Rowan, John F Seymour, Kate Burbury, Dennis Carney, Constantine S Tam

Journal article  |  2017  |  Leukemia & Lymphoma

Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes

Jason A Trubiano, Michael Dickinson, Karin A Thursky, Timothy Spelman, John F Seymour, Monica A Slavin, Leon J Worth

Journal article  |  2017  |  Leukemia & Lymphoma

When to treat patients with relapsed follicular lymphoma

Chan Yoon Cheah, John F Seymour

Journal article  |  2017  |  Expert Review of Hematology

Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia

Kenneth F Bradstock, Alec Morley, Karen Byth, Jeff Szer, Ian Prosser, Paul Cannell, Ian Irving, John F Seymour

Journal article  |  2016  |  Contemporary Clinical Trials Communications

Transformed Lymphoma

Mary Ann Anderson, Piers Blombery, John F Seymour

Journal article  |  2016  |  Hematology/Oncology Clinics of North America

Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience

Wirawan Jeong, Peter Haywood, Naranie Shanmuganathan, Julian Lindsay, Karen Urbancic, Michelle R Ananda-Rajah, Sharon CA Chen, Ashish Bajel, David Ritchie, Andrew Grigg, John F Seymour, Anton Y Peleg, David CM Kong, Monica A Slavin

Journal article  |  2016  |  Journal of Antimicrobial Chemotherapy

Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement

Tarec Christoffer El-Galaly, Chan Y Cheah, Martin Hutchings, Nabegh George Mikhaeel, Kerry J Savage, Laurie H Sehn, Sally Barrington, Jakob W Hansen, Mette O Poulsen, Daniel Smith, Kirsty Rady, Karen J Mylam, Thomas S Larsen, Staffan Holmberg, Maja B Juul, Sabrina Cordua, Michael R Clausen, Kristina B Jensen, Martin Bogsted, Hans E Johnsen, et al.

Journal article  |  2016  |  British Journal of Haematology

Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

U Vitolo, JF Seymour, M Martelli, G Illerhaus, T Illidge, E Zucca, E Campo, M Ladetto

Journal article  |  2016  |  Annals of Oncology

Effective mitigation of tumor lysis syndrome with gradual venetoclax dose ramp, prophylaxis, and monitoring in patients with chronic lymphocytic leukemia

John F Seymour

Journal article  |  2016  |  Annals of Hematology

Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial

Clementine Sarkozy, Marek Trneny, Luc Xerri, Nick Wickham, Pierre Feugier, Sirpa Leppa, Pauline Brice, Pierre Soubeyran, Maria Gomes Da Silva, Christiane Mounier, Fritz Offner, Jehan Dupuis, Dolores Caballero, Danielle Canioni, Marlton Paula, Richard Delarue, Pierre Zachee, John Seymour, Gilles Salles, Herve Tilly

Journal article  |  2016  |  Journal of Clinical Oncology

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

Mary Ann Anderson, Jing Deng, John F Seymour, Constantine Tam, Su Young Kim, Joshua Fein, Lijian Yu, Jennifer R Brown, David Westerman, Eric G Si, Ian J Majewski, David Segal, Sari L Heitner Enschede, David CS Huang, Matthew S Davids, Anthony Letai, Andrew W Roberts

Journal article  |  2016  |  Blood

New Agents to Treat Chronic Lymphocytic Leukemia REPLY

Andrew W Roberts, Matthew S Davids, John F Seymour

Journal article  |  2016  |  New England Journal of Medicine

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Steven Coutre, John F Seymour, Talha Munir, Soham D Puvvada, Clemens-Martin Wendtner, Andrew W Roberts, Wojciech Jurczak, Stephen P Mulligan, Sebastian Boettcher, Mehrdad Mobasher, Ming Zhu, Monali Desai, Brenda Chyla, Maria Verdugo, Sari Heitner Enschede, Elisa Cerri, Rod Humerickhouse, et al.

Journal article  |  2016  |  The Lancet Oncology

Mantle Cell Lymphoma

Chan Yoon Cheah, John F Seymour, Michael L Wang

Journal article  |  2016  |  Journal of Clinical Oncology

Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia

Constantine S Tam, John F Seymour, Andrew W Roberts

Journal article  |  2016  |  Seminars in Oncology

Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study

Emmanuel Bachy, Jane A Estell, Eric Van de Neste, Reda Bouabdallah, Joan Bargay, Alain Delmer, Benedicte Gelas-Dore, Maria Gomes da Silva, Olivier Fitoussi, David Belada, Herve Maisonneuve, Tanin Intragumtornchai, Thierry Lamy, Peggy Dartigues, John Francis Seymour, Gilles Salles

Journal article  |  2016  |  American Journal of Hematology

Challenging historical perspectives of the 24-h chemotherapy day: Flexible chemotherapy dose-timing guidelines

Marliese Alexander, Frank Coenders, Danielle Murray, Sue Kirsa, John Seymour

Journal article  |  2016  |  Asia-Pacific Journal of Clinical Oncology

Disseminated visceral varicella zoster virus presenting with the constellation of colonic pseudo-obstruction, acalculous cholecystitis and syndrome of inappropriate ADH secretion

MR Braude, JA Trubiano, A Heriot, M Dickinson, D Carney, JF Seymour, CS Tam

Journal article  |  2016  |  Internal Medicine Journal

Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit

Tan N Doan, Carl MJ Kirkpatrick, Patricia Walker, Monica A Slavin, Michelle R Ananda-Rajah, C Orla Morrissey, Karen F Urbancic, Andrew Grigg, Andrew Spencer, Jeffrey Szer, John F Seymour, David CM Kong

Journal article  |  2016  |  Journal of Antimicrobial Chemotherapy

The impact of HLA class I and EBV latency-II antigen-specific CD8( ) T cells on the pathogenesis of EBV Hodgkin lymphoma

K Jones, L Wockner, RM Brennan, C Keane, PK Chattopadhyay, M Roederer, DA Price, DK Cole, B Hassan, K Beck, D Gottlieb, DS Ritchie, JF Seymour, F Vari, P Crooks, SR Burrows, MK Gandhi

Journal article  |  2016  |  Clinical & Experimental Immunology

The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial

Simon Rule, Paul Smith, Peter WM Johnson, Simon Bolam, George Follows, Joanne Gambell, Peter Hillmen, Andrew Jack, Stephen Johnson, Amy A Kirkwood, Anton Kruger, Christopher Pocock, John F Seymour, Milena Toncheva, Jan Walewski, David Linch

Journal article  |  2016  |  Haematologica

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Andrew W Roberts, Matthew S Davids, John M Pagel, Brad S Kahl, Soham D Puvvada, John F Gerecitano, Thomas J Kipps, Mary Ann Anderson, Jennifer R Brown, Lori Gressick, Shekman Wong, Martin Dunbar, Ming Zhu, Monali B Desai, Elisa Cerri, Sari Heitner Enschede, Rod A Humerickhouse, William G Wierda, John F Seymour

Journal article  |  2016  |  New England Journal of Medicine

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

Kirsten Fischer, Jasmin Bahlo, Anna Maria Fink, Valentin Goede, Carmen Diana Herling, Paula Cramer, Petra Langerbeins, Julia von Tresckow, Anja Engelke, Christian Maurer, Gabor Kovacs, Marco Herling, Eugen Tausch, Karl-Anton Kreuzer, Barbara Eichhorst, Sebastian Boettcher, John F Seymour, Paolo Ghia, Paula Marlton, Michael Kneba, et al.

Journal article  |  2016  |  Blood

Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy

Thomas E Lew, Chan Y Cheah, Dennis A Carney, H Miles Prince, Max Wolf, Ali Bazargan, E Henry Januszewicz, Robin Filshie, David Westerman, John F Seymour, Constantine S Tam

Journal article  |  2016  |  Leukemia & Lymphoma

Copper deficiency mimicking myelodysplastic syndrome

Kirsty Rady, David Westerman, Piers Blombery, Paul Turner, John Seymour

Journal article  |  2016  |  Leukemia & Lymphoma

Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasms

Nicole Wong Doo, Enes Makalic, JiHoon E Joo, Claire M Vajdic, Daniel F Schmidt, Ee Ming Wong, Chol-Hee Jung, Gianluca Severi, Daniel J Park, Jessica Chung, Laura Baglietto, Henry Miles Prince, John F Seymour, Constantine Tam, John L Hopper, Dallas R English, Roger L Milne, Simon J Harrison, Melissa C Southey, Graham G Giles

Journal article  |  2016  |  Epigenomics

Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target

Fortunato Morabito, Massimo Gentile, John F Seymour, Aaron Polliack

Journal article  |  2015  |  Leukemia & Lymphoma

Dasatinib therapy can result in significant pulmonary toxicity

Maciek Tatarczuch, Kate Burbury, Louise Creati, Elchanan H Januszewicz, John F Seymour

Journal article  |  2015  |  American Journal of Hematology

Fast-track rapid warfarin reversal for elective surgery: extending the efficacy profile to high-risk patients with cancer

TJ Byrne, B Riedel, HM Ismail, A Heriot, R Dauer, D Westerman, JF Seymour, K Kenchington, K Burbury

Journal article  |  2015  |  Anaesthesia and Intensive Care

Epidemiology of invasive fungal disease in lymphoproliferative disorders

Jasmine C Teng, Monica A Slavin, Benjamin W Teh, Senthil M Lingaratnam, Michelle R Ananda-Rajah, Leon J Worth, John F Seymour, Karin A Thursky

Journal article  |  2015  |  Haematologica

Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study

Colm Keane, Frank Vari, Mark Hertzberg, Kim-Anh Le Cao, Michael R Green, Erica Han, John F Seymour, Rodney J Hicks, Devinder Gill, Pauline Crooks, Clare Gould, Kimberley Jones, Lyn R Griffiths, Dipti Talaulikar, Sanjiv Jain, Josh Tobin, Maher K Gandhi

Journal article  |  2015  |  The Lancet Haematology

Declining Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Cancer

Ie-Wen Sim, Kerrie M Sanders, Gelsomina L Borromeo, John F Seymour, Peter R Ebeling

Journal article  |  2015  |  The Journal of Clinical Endocrinology & Metabolism

The molecular pathogenesis of B-cell non-Hodgkin lymphoma

Piers A Blombery, Meaghan Wall, John F Seymour

Journal article  |  2015  |  European Journal of Haematology

Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20( ) lymphoid malignancies

Andrew W Roberts, Ranjana H Advani, Brad S Kahl, Daniel Persky, John W Sweetenham, Dennis A Carney, Jianning Yang, Todd B Busman, Sari H Enschede, Roderick A Humerickhouse, John F Seymour

Journal article  |  2015  |  British Journal of Haematology

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial

Harry J Iland, Marnie Collins, Ken Bradstock, Shane G Supple, Alberto Catalano, Mark Hertzberg, Peter Browett, Andrew Grigg, Frank Firkin, Lynda J Campbell, Amanda Hugman, John Reynolds, Juliana Di Iulio, Campbell Tiley, Kerry Taylor, Robin Filshie, Michael Seldon, John Taper, Jeff Szer, John Moore, et al.

Journal article  |  2015  |  The Lancet Haematology

Stage I-II follicular lymphoma: an endangered species?

Peter McLaughlin, John F Seymour

Journal article  |  2015  |  Leukemia & Lymphoma

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Herve Dombret, John F Seymour, Aleksandra Butrym, Agnieszka Wierzbowska, Dominik Selleslag, Jun Ho Jang, Rajat Kumar, James Cavenagh, Andre C Schuh, Anna Candoni, Christian Recher, Irwindeep Sandhu, Teresa Bernal del Castillo, Haifa Kathrin Al-Ali, Giovanni Martinelli, Jose Falantes, Richard Noppeney, Richard M Stone, Mark D Minden, Heidi McIntyre, et al.

Journal article  |  2015  |  Blood

An uncomplicated pregnancy in a woman with smoldering Waldenstrom macroglobulinemia

Kirsty Rady, Euan Wallace, John F Seymour

Journal article  |  2015  |  Leukemia & Lymphoma

Follicular lymphoma: is peripheral blood involvement still an adverse prognostic factor in the rituximab era?

Estella Matutes, John F Seymour, Aaron Polliack

Journal article  |  2015  |  Leukemia & Lymphoma

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes

CY Cheah, D Chihara, JE Romaguera, NH Fowler, JF Seymour, FB Hagemeister, RE Champlin, ML Wang

Journal article  |  2015  |  Annals of Oncology

How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?

Nimish Shah, Constantine Tam, John F Seymour, Simon Rule

Journal article  |  2015  |  Leukemia & Lymphoma

Central Nervous System Prophylaxis in Non-Hodgkin Lymphoma: Who, What, and When?

Chan Yoon Cheah, John F Seymour

Journal article  |  2015  |  Current Oncology Reports

Large B-cell lymphoma: is the future written in the blood?

Sarah-Jane Dawson, John F Seymour

Journal article  |  2015  |  The Lancet Oncology

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

Rami S Komrokji, John F Seymour, Andrew W Roberts, Martha Wadleigh, L Bik To, Robyn Scherber, Elyce Turba, Andrew Dorr, Joy Zhu, Lixia Wang, Tanya Granston, Mary S Campbell, Ruben A Mesa

Journal article  |  2015  |  Blood

Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study

Chan Yoon Cheah, David Belada, Michelle A Fanale, Andrea Janikova, Myron S Czucman, Ian W Flinn, Amy V Kapp, Avi Ashkenazi, Sean Kelley, Gordon L Bray, Scott Holden, John F Seymour

Journal article  |  2015  |  The Lancet Haematology

Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma

Xiaolei Zhou, Jianmin Wang, Jessica Zhang, Catherine Copley-Merriman, Yasuhiro Torigoe, Carolina Reyes, John F Seymour, Fritz C Offner, Marek Trneny, Gilles Andre Salles

Journal article  |  2015  |  Hematology

Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study

Simon Wu, Desmond Chee, Anna Ugalde, Phyllis Butow, John Seymour, Penelope Schofield

Journal article  |  2015  |  Palliative and Supportive Care

HLA class I associations with EBV post-transplant lymphoproliferative disorder

Kimberley Jones, Leesa Wockner, Alycia Thornton, David Gottlieb, David S Ritchie, John F Seymour, Gayathri Kumarasinghe, Maher K Gandhi

Journal article  |  2015  |  Transplant Immunology

Immunochemotherapy in Waldenstrom macroglobulinemia - still the backbone of treatment

Christian Buske, JF Seymour

Journal article  |  2015  |  Leukemia & Lymphoma

Editor in Chief: Response to Eyre et al. "ALK-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease"

Rachel Conyers, Aparna Rao, Benjamin Solomon, John F Seymour

Journal article  |  2015  |  European Journal of Haematology

The utility and limitations of F-18-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review

Chan Y Cheah, Michael S Hofman, John F Seymour, David S Ritchie, Michael Dickinson, Andrew Wirth, H Miles Prince, Max Wolf, Elchanan H Januszcewicz, Dennis A Carney, Kirsten E Herbert, Simon J Harrison, Kate L Burbury, Constantine S Tam

Journal article  |  2015  |  Leukemia & Lymphoma

Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis

Senthil M Lingaratnam, Monica A Slavin, Karin A Thursky, Benjamin W Teh, Gabrielle M Haeusler, John F Seymour, Danny Rischin, Leon J Worth

Journal article  |  2015  |  Leukemia & Lymphoma

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling

Julie R McMullen, Esther JH Boey, Jenny YY Ooi, John F Seymour, Michael J Keating, Constantine S Tam

Journal article  |  2014  |  Blood

A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia

Kenneth F Bradstock, Emma Link, Marnie Collins, Juliana Di Iulio, Ian D Lewis, Anthony Schwarer, Arno Enno, Paula Marlton, Uwe Hahn, Jeff Szer, Gavin Cull, John F Seymour

Journal article  |  2014  |  British Journal of Haematology

Favorable Outcomes from Allogeneic and Autologous Stem Cell Transplantation for Patients with Transformed Nonfollicular Indolent Lymphoma

Diego Villa, Anupkumar George, John F Seymour, Cynthia L Toze, Michael Crump, Christina Lee, Rena Buckstein, Douglas A Stewart, David MacDonald, Ronan Foley, Anargyros Xenocostas, Mitchell Sabloff, Neil Chua, Felix Couture, Jean E Larouche, Sandra Cohen, Kerry J Savage, Joseph M Connors, Tony Panzarella, Dennis A Carney, et al.

Journal article  |  2014  |  Biology of Blood and Marrow Transplantation

Adding weight to a sinking ship: more reasons not to perform routine surveillance imaging in patients with diffuse large B-cell lymphoma in remission

Chan Y Cheah, John F Seymour

Journal article  |  2014  |  Leukemia & Lymphoma

ABT-199 for chronic lymphocytic leukemia.

John Seymour

Journal article  |  2014  |  Clinical Advances in Hematology and Oncology

A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma

CY Cheah, KE Herbert, K O'Rourke, GA Kennedy, A George, PL Fedele, M Gilbertson, SY Tan, DS Ritchie, SS Opat, HM Prince, M Dickinson, K Burbury, M Wolf, EH Januszewicz, CS Tam, DA Westerman, DA Carney, SJ Harrison, JF Seymour

Journal article  |  2014  |  British Journal of Cancer

Primary breast lymphoma

Chan Y Cheah, Belinda A Campbell, John F Seymour

Journal article  |  2014  |  Cancer Treatment Reviews

R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes

John F Seymour, Michael Pfreundschuh, Marek Trneny, Laurie H Sehn, John Catalano, Eva Csinady, Nicola Moore, Bertrand Coiffier

Journal article  |  2014  |  Haematologica

The Choice of Multiple Myeloma Induction Therapy Affects the Frequency and Severity of Oral Mucositis After Melphalan-Based Autologous Stem Cell Transplantation

Shaun Fleming, Simon J Harrison, Piers Blombery, Trish Joyce, Kerrie Stokes, John F Seymour, H Miles Prince, David Ritchie

Journal article  |  2014  |  Clinical Lymphoma Myeloma and Leukemia

Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial

KE Herbert, L Demosthenous, G Wiesner, E Link, DA Westerman, N Came, DS Ritchie, S Harrison, JF Seymour, HM Prince

Journal article  |  2014  |  Bone Marrow Transplantation

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

JF Seymour, DW Kim, E Rubin, A Haregewoin, J Clark, P Watson, T Hughes, I Dufva, JL Jimenez, F-X Mahon, P Rousselot, J Cortes, G Martinelli, Cristina Papayannidis, A Nagler, FJ Giles

Journal article  |  2014  |  Blood Cancer Journal

Prognosis for patients with CML and > 10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline

Susan Branford, David T Yeung, Wendy T Parker, Nicola D Roberts, Leanne Purins, Jodi A Braley, Haley K Altamura, Alexandra L Yeoman, Jasmina Georgievski, Bronte A Jamison, Stuart Phillis, Zoe Donaldson, Mary Leong, Linda Fletcher, John F Seymour, Andrew P Grigg, David M Ross, Timothy P Hughes

Journal article  |  2014  |  Blood

A new prognostic score for CLL

Constantine S Tam, John F Seymour

Journal article  |  2014  |  Blood

De novo B-cell prolymphocytic leukemia with central nervous system involvement

Maciek Tatarczuch, Piers Blombery, John F Seymour

Journal article  |  2014  |  LEUKEMIA & LYMPHOMA

Clinical utility of Aspergillus galactomannan and PCR in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignancies

Siow-Chin Heng, Sharon C-A Chen, C Orla Morrissey, Karin Thursky, Renee L Manser, Harini D De Silva, Catriona L Halliday, John F Seymour, Roger L Nation, David CM Kong, Monica A Slavin

Journal article  |  2014  |  Diagnostic Microbiology and Infectious Disease

Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy

Chan Y Cheah, Michael Dickinson, Michael S Hofman, Anupkumar George, David S Ritchie, H Miles Prince, David Westerman, Simon J Harrison, Kate Burbury, Max Wolf, Henry Januszewicz, Kirsten E Herbert, Dennis A Carney, Constantine Tam, John F Seymour

Journal article  |  2014  |  ANNALS OF HEMATOLOGY

Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib

Chan Y Cheah, Kate Burbury, Jane F Apperley, Francoise Huguet, Vincenzo Pitini, Martine Gardembas, David M Ross, Donna Forrest, Philippe Genet, Philippe Rousselot, Nigel Patton, Graeme Smith, Cynthia E Dunbar, Sawa Ito, Ricardo CT Aguiar, Olatoyosi Odenike, Alla Gimelfarb, Nicholas CP Cross, John F Seymour

Journal article  |  2014  |  Blood

A case of delayed methotrexate clearance following administration of a complementary medication containing chlorophyll

Sally L Brooks, Julie Sanders, John F Seymour, James D Mellor

Journal article  |  2014  |  Journal of Oncology Pharmacy Practice

The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale

Andrea Gallamini, Sally F Barrington, Alberto Biggi, Stephane Chauvie, Lale Kostakoglu, Michele Gregianin, Michel Meignan, George N Mikhaeel, Annika Loft, Jan M Zaucha, John F Seymour, Michael S Hofman, Luigi Rigacci, Alessandro Pulsoni, Morton Coleman, Eldad J Dann, Livio Trentin, Olivier Casasnovas, Chiara Rusconi, Pauline Brice, et al.

Journal article  |  2014  |  Haematologica

Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma

Clementine Sarkozy, John Francis Seymour, Christophe Ferme, Dolores Caballero, Herve Ghesquieres, Sirpa Leppa, Richard Delarue, Lars Moller Pedersen, Christiane Mounier, Maria Gomes Da Silva, Catherine Chassagne-Clement, Marie Maerevoet, Gilles Salles

Journal article  |  2014  |  Blood

Challenges and outcomes of a randomized study of early nutrition support during autologous stem-cell transplantation

N Kiss, JF Seymour, HM Prince, G Dutu

Journal article  |  2014  |  CURRENT ONCOLOGY

Myeloma and pregnancy: strange bedfellows?

Amit S Khot, H Miles Prince, Simon J Harrison, John F Seymour

Journal article  |  2014  |  Leukemia & Lymphoma

Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: the need for continued vigilance

Edward Chew, Karin Thursky, John F Seymour

Journal article  |  2014  |  Leukemia & Lymphoma

Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes

John F Seymour, John M Bennett, Alan F List, Ghulam J Mufti, Steven D Gore, Pierre Fenaux, Valeria Santini, Joel Hetzer, Stephen Songer, Barry S Skikne, Charles L Beach

Journal article  |  2014  |  British Journal of Haematology

Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan

Haruyuki Ishii, John F Seymour, Ryushi Tazawa, Yoshikazu Inoue, Naoyuki Uchida, Aya Nishida, Yoshihito Kogure, Takeshi Saraya, Keisuke Tomii, Toshinori Takada, Yuko Itoh, Masayuki Hojo, Toshio Ichiwata, Hajime Goto, Koh Nakata

Journal article  |  2014  |  BMC Pulmonary Medicine

Prognostic impact of monocyte count at presentation in mantle cell lymphoma

Anupkumar George, Henry Miles Prince, Jeff Szer, Max Wolf, Elchanan H Januszewicz, John F Seymour, David S Ritchie

Journal article  |  2014  |  British Journal of Haematology

Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis

Clementine Sarkozy, Lucile Baseggio, Pierre Feugier, Evelyne Callet-Bauchu, Lionel Karlin, John F Seymour, Laure Lebras, Anne-Sophie Michallet, Fritz Offner, Olivier Dumas, Alexandra Traverse-Glehen, Martine Ffrench, Armando Lopez-Guillermo, Francoise Berger, Bertrand Coiffier, Pascale Felman, Gilles Salles

Journal article  |  2014  |  British Journal of Haematology

Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?

Chan Y Cheah, John F Seymour

Journal article  |  2014  |  Leukemia & Lymphoma

Optimal approach for high-risk acute promyelocytic leukemia

Harry J Iland, John F Seymour, Andrew Wei

Journal article  |  2014  |  Current Opinion in Hematology

Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care

Harry J Iland, Andrew Wei, John F Seymour

Journal article  |  2014  |  Best Practice & Research Clinical Haematology

Challenges of phase III trial design for novel treatments in diseases with no standard treatment: The AZA-001 myelodysplasia study model

Pierre Fenaux, John F Seymour, Valeria Santini, Lew Silverman, Steven Gore, Alan List, Guillermo Sanz, Ghulam J Mufti, Eli Estey, Arlene S Swern, CL Beach, Eva Hellstrom-Lindberg

Journal article  |  2014  |  Leukemia Research

Primary testicular lymphoma

Chan Y Cheah, Andrew Wirth, John F Seymour

Journal article  |  2014  |  Blood

B-cell prolymphocytic leukemia (B-PLL) and T-cell prolymphocytic leukemia (T-PLL)

G Ott, ED Hsi, JF Seymour, G Hopfinger

Book Chapter  |  2014

Bone Marrow Biopsy for the Initial Staging of Patients With Lymphoma: Too Soon to Toss the Trephine

Chan Y Cheah, John F Seymour

Journal article  |  2013  |  Oncology (Williston Park, N.Y.)

High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?

Anupkumar George, Constantine S Tam, John F Seymour

Journal article  |  2013  |  Leukemia and Lymphoma

Interview: Exploring multiple pathways to find new cures

John F Seymour

Journal article  |  2013  |  International Journal of Hematology

Concerns regarding data supporting recent Pneumocystis jirovecii prophylaxis guidelines

John F Seymour

Journal article  |  2013  |  ANNALS OF HEMATOLOGY

Evaluating the place of 18-fluoro-2-deoxy-D-glucose positron emission tomography scanning in primary staging and beyond in patients with follicular lymphoma

John F Seymour, Judith Trotman, Michael S Hofman

Journal article  |  2013  |  Leukemia and Lymphoma

Chemotherapy Versus Autologous Stem-Cell Transplantation for the Treatment of Transformed Follicular Lymphoma in the Rituximab Era

Constantine S Tam, Alan Herschtal, Michael Dickinson, Anupkumar George

Journal article  |  2013  |  Journal of Clinical Oncology

A case of chronic lymphocytic leukemia associated with systemic light chain amyloidosis

Eric Wong, Lee Ping Chew, John F Seymour

Journal article  |  2013  |  Leukemia and Lymphoma

High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma

Raghava Kashyap, Eddie Lau, Anupkumar George, John F Seymour, Stephen Lade, Rodney J Hicks, Michael S Hofman

Journal article  |  2013  |  EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rituximab for the treatment of follicular lymphoma

Chan Y Cheah, Senthil Lingaratnam, John F Seymour

Journal article  |  2013  |  Future Oncology

Refining the predictors of risk for central nervous system involvement in patients with mantle cell lymphoma

Chan Yoon Cheah, John F Seymour

Journal article  |  2013  |  Leukemia and Lymphoma

Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network

CY Cheah, A George, E Gine, A Chiappella, HC Kluin-Nelemans, W Jurczak, K Krawczyk, H Mocikova, P Klener, D Salek, J Walewski, M Szymczyk, L Smolej, RL Auer, DS Ritchie, L Arcaini, ME Williams, M Dreyling, JF Seymour

Journal article  |  2013  |  Annals of Oncology

All is not lost - the improving outcome of patients with chronic lymphocytic leukaemia failing frontline therapy with fludarabine, cyclophosphamide and rituximab

Chan Y Cheah, Thomas E Lew, Rebecca Lee, Constantine S Tam, John F Seymour, Dennis A Carney

Journal article  |  2013  |  European Journal of Haematology

Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis

Gabrielle M Haeusler, Monica A Slavin, John F Seymour, Senthil Lingaratnam, Benjamin W Teh, Constantine S Tam, Karin A Thursky, Leon J Worth

Journal article  |  2013  |  EUROPEAN JOURNAL OF HAEMATOLOGY

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

David M Ross, Susan Branford, John F Seymour, Anthony P Schwarer, Christopher Arthur, David T Yeung, Dang Phuong, Jarrad M Goyne, Cassandra Slader, Robin J Filshie, Anthony K Mills, Junia V Melo, Deborah L White, Andrew P Grigg, Timothy P Hughes

Journal article  |  2013  |  Blood

Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy

CY Cheah, MS Hofman, M Dickinson, A Wirth, D Westerman, SJ Harrison, K Burbury, M Wolf, H Januszewicz, K Herbert, HM Prince, DA Carney, DS Ritchie, RJ Hicks, JF Seymour

Journal article  |  2013  |  BRITISH JOURNAL OF CANCER

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

Steven D Gore, Pierre Fenaux, Valeria Santini, John M Bennett, Lewis R Silverman, John F Seymour, Eva Hellstrom-Lindberg, Arlene S Swern, Charles L Beach, Alan F List

Journal article  |  2013  |  Haematologica

Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy

Siow-Chin Heng, Monica A Slavin, Daoud Al-Badriyeh, Sue Kirsa, John F Seymour, Andrew Grigg, Karin Thursky, Ashish Bajel, Roger L Nation, David CM Kong

Journal article  |  2013  |  Journal of Antimicrobial Chemotherapy

Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma

Nicole Wong Doo, Philip A Thompson, H Miles Prince, John F Seymour, David Ritchie, Kerrie Stokes, Kate Burbury, Max Wolf, Trish Joyce, Simon J Harrison

Journal article  |  2013  |  Leukemia and Lymphoma

Role of Arsenic Trioxide in Acute Promyelocytic Leukemia

Harry J Iland, John F Seymour

Journal article  |  2013  |  CURRENT TREATMENT OPTIONS IN ONCOLOGY

Extra-nodal lymphoma in rare localisations: bone, breast and testes

John F Seymour

Journal article  |  2013  |  Hematological Oncology

Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML

Susan Branford, David T Yeung, David M Ross, Jodi A Prime, Chani R Field, Haley K Altamura, Alexandra L Yeoman, Jasmina Georgievski, Bronte A Jamison, Stuart Phillis, Brad Sullivan, Nancy E Briggs, Mark Hertzberg, John F Seymour, John Reynolds, Timothy P Hughes

Journal article  |  2013  |  Blood

Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study

A Wirth, M Gospodarowicz, BMP Aleman, M Bressel, A Ng, M Chao, RT Hoppe, C Thieblemont, R Tsang, L Moser, L Specht, T Szpytma, A Lennard, JF Seymour, E Zucca

Journal article  |  2013  |  ANNALS OF ONCOLOGY

Treatment of chronic myelomonocytic leukemia with azacitidine

Eric Wong, John F Seymour, Melita Kenealy, David Westerman, Kirsten Herbert, Michael Dickinson

Journal article  |  2013  |  Leukemia and Lymphoma

Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group

Arjan A van de Loosdrecht, Robin Ireland, Wolfgang Kern, Matteo G Della Porta, Canan Alhan, Jan Sebastian Balleisen, Peter Bettelheim, David T Bowen, Kate Burbury, Lisa Eidenschink, Mario Cazzola, Spencer SC Chu, Matthew Cullen, Jevon A Cutler, Angelika M Drager, Jean Feuillard, Pierre Fenaux, Patricia Font, Ulrich Germing, Detlef Haase, et al.

Journal article  |  2013  |  Leukemia and Lymphoma

Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells

KE Herbert, P Gambell, EK Link, A Mouminoglu, DM Wall, SJ Harrison, DS Ritchie, JF Seymour, HM Prince

Journal article  |  2013  |  Bone Marrow Transplantation

Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy

Victoria Ling, Alan K Burnett, Ken Bradstock, John F Seymour, Robert K Hills, Andrew Wei

Journal article  |  2013  |  British Journal of Haematology

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J Souers, Joel D Leverson, Erwin R Boghaert, Scott L Ackler, Nathaniel D Catron, Jun Chen, Brian D Dayton, Hong Ding, Sari H Enschede, Wayne J Fairbrother, David CS Huang, Sarah G Hymowitz, Sha Jin, Seong Lin Khaw, Peter J Kovar, Lloyd T Lam, Jackie Lee, Heather L Maecker, Kennan C Marsh, Kylie D Mason, et al.

Journal article  |  2013  |  Nature Medicine

A Risk-Adapted Protocol for Delayed Administration of Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation

Amit Khot, Michael Dickinson, Kerrie Stokes, Simon Harrison, Kate Burbury, Shaun Fleming, Dominic Wall, Peter Gambell, H Miles Prince, John F Seymour, David Ritchie

Journal article  |  2013  |  Clinical Lymphoma & Myeloma

Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic Lymphoma

Veronique Leblond, Steve Johnson, Sylvie Chevret, Adrian Copplestone, Simon Rule, Olivier Tournilhac, John Francis Seymour, Russell D Patmore, David Wright, Pierre Morel, Marie-Sarah Dilhuydy, Sara Willoughby, Caroline Dartigeas, Marion Malphettes, Bruno Royer, Maeve Ewings, Guy Pratt, Julie Lejeune, Florence Nguyen-Khac, Sylvain Choquet, et al.

Journal article  |  2013  |  Journal of Clinical Oncology

Under-recognition of platelet dysfunction in myelodysplastic syndromes: are we only seeing the tip of the iceberg?

Kate L Burbury, John F Seymour, Ray Dauer, David A Westerman

Journal article  |  2013  |  Leukemia and Lymphoma

Rasburicase Causing Severe Oxidative Hemolysis and Methemoglobinemia in a Patient with Previously Unrecognized Glucose-6-Phosphate Dehydrogenase Deficiency

Chan Y Cheah, Thomas E Lew, John F Seymour, Kate Burbury

Journal article  |  2013  |  Acta Haematologica

Reproductive concerns of children and adolescents with cancer: challenges and potential solutions

CJ Stern, R Conyers, L Orme, S Barak, F Agresta, JF Seymour

Journal article  |  2013  |  Clinical Oncology in Adolescents and Young Adults

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms

Herve Ghesquieres, Guillaume Cartron, John Francis Seymour, Marie-Helene Delfau-Larue, Fritz Offner, Pierre Soubeyran, Aurore Perrot, Pauline Brice, Reda Bouabdallah, Anne Sonet, Jehan Dupuis, Olivier Casasnovas, John Vincent Catalano, Alain Delmer, Fabrice Jardin, Aurelie Verney, Peggy Dartigues, Gilles Salles

Journal article  |  2012  |  Blood

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

Harry J Iland, Ken Bradstock, Shane G Supple, Alberto Catalano, Marnie Collins, Mark Hertzberg, Peter Browett, Andrew Grigg, Frank Firkin, Amanda Hugman, John Reynolds, Juliana Di Iulio, Campbell Tiley, Kerry Taylor, Robin Filshie, Michael Seldon, John Taper, Jeff Szer, John Moore, John Bashford, et al.

Journal article  |  2012  |  Blood

Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients

Stephen D Guy, Adrian R Tramontana, Leon J Worth, Eddie Lau, Rodney J Hicks, John F Seymour, Karin A Thursky, Monica A Slavin

Journal article  |  2012  |  EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Paraneoplastic large vessel arteritis complicating myelodysplastic syndrome

Shaun Fleming, Eva Hellstrom-Lindberg, Kate Burbury, John F Seymour

Journal article  |  2012  |  Leukemia and Lymphoma

No evidence for DNA methylation of the ATM promoter CpG island in chronic lymphocytic leukemia

Thomas Mikeska, Dennis A Carney, John F Seymour, Alexander Dobrovic

Journal article  |  2012  |  Leukemia and Lymphoma

Local experience with the novel human anti-CD20 antibody, ofatumumab, as salvage treatment for patients with heavily pretreated chronic lymphocytic leukaemia

CY Cheah, DA Carney, SM Lim, H Januszewicz, J Scarlett, JF Seymour

Journal article  |  2012  |  Internal Medicine Journal

Rapid detection of FLT3 exon 20 tyrosine kinase domain mutations in patients with acute myeloid leukemia by high-resolution melting analysis

Angela Y-C Tan, Stephen Q Wong, Charlotte Guldborg Nyvold, Dennis A Carney, Andrew Wei, John F Seymour, Peter Hokland, undefined Westerman, Alexander Dobrovic

Journal article  |  2012  |  Leukemia and Lymphoma

Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro

R Ralli, KM Banks, AP Wiegmans, D Carney, JF Seymour, RW Johnstone, AE Alsop

Journal article  |  2012  |  Leukemia

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

U Germing, M Lauseker, B Hildebrandt, A Symeonidis, J Cermak, P Fenaux, C Kelaidi, M Pfeilstoecker, T Noesslinger, M Sekeres, J Maciejewski, D Haase, J Schanz, J Seymour, M Kenealy, R Weide, M Luebbert, U Platzbecker, P Valent, K Goetze, et al.

Journal article  |  2012  |  Leukemia

Osteolytic bone lesions in non-transformed chronic lymphocytic leukemia are not as rare as suggested

John F Seymour

Journal article  |  2012  |  Leukemia and Lymphoma

Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy

BA Campbell, C Hornby, J Cunninghame, M Burns, M MacManus, G Ryan, E Lau, JF Seymour, A Wirth

Journal article  |  2012  |  Annals of Oncology

When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload?

RJ Bird, M Kenealy, C Forsyth, J Wellwood, MF Leahy, JF Seymour, LB To

Journal article  |  2012  |  Internal Medicine Journal

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Andrew W Roberts, John F Seymour, Jennifer R Brown, William G Wierda, Thomas J Kipps, Seong Lin Khaw, Dennis A Carney, Simon Z He, David CS Huang, Hao Xiong, Yue Cui, Todd A Busman, Evelyn M McKeegan, Andrew P Krivoshik, Sari H Enschede, Rod Humerickhouse

Journal article  |  2012  |  JOURNAL OF CLINICAL ONCOLOGY

Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia

Harry Iland, Ken Bradstock, John Seymour, Mark Hertzberg, Andrew Grigg, Kerry Taylor, John Catalano, Paul Cannell, Noemi Horvath, Sandra Deveridge, Peter Browett, Tim Brighton, Li Chong, Francisca Springall, Juliet Ayling, Alberto Catalano, Shane Supple, Marnie Collins, Juliana Di Iulio, John Reynolds

Journal article  |  2012  |  Haematologica

Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML

A van der Jagt, J Muirhead, JF Seymour, KF Bradstock, E Paul, A Wei

Journal article  |  2012  |  Leukemia

Impact of a novel nurse-led prechemotherapy education intervention (ChemoEd) on patient distress, symptom burden, and treatment-related information and support needs: results from a randomised, controlled trial

S Aranda, M Jefford, P Yates, K Gough, J Seymour, P Francis, C Baravelli, S Breen, P Schofield

Journal article  |  2012  |  ANNALS OF ONCOLOGY

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

Simon J Harrison, Hang Quach, Emma Link, John F Seymour, David S Ritchie, Sam Ruell, Joanne Dean, Henry Januszewicz, Ricky Johnstone, Paul Neeson, Michael Dickinson, Jean Nichols, H Miles Prince

Journal article  |  2011  |  Blood

Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features

David M Ross, Paul A Bartley, Jarrad Goyne, Alexander A Morley, John F Seymour, Andrew P Grigg

Journal article  |  2011  |  Haematologica

ABVD versus BEACOPP for Hodgkin's Lymphoma

Constantine S Tam, Alan Herschtal, John F Seymour

Journal article  |  2011  |  New England Journal of Medicine

Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants

Judith Trotman, Marion Fournier, Thierry Lamy, John Francis Seymour, Anne Sonet, Andrea Janikova, Ofer Shpilberg, Emmanuel Gyan, Herve Tilly, Jane Estell, Cecily Forsyth, Didier Decaudin, Bettina Fabiani, Jean Gabarre, Bruno Salles, Eric Van den Neste, Danielle Canioni, Etienne Garin, Michael Fulham, Thierry Vander Borght, et al.

Journal article  |  2011  |  Journal of Clinical Oncology

Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine

Shane A Gangatharan, Dennis A Carney, Lynda J Campbell, H Miles Prince, Melita K Kenealy, John F Seymour

Journal article  |  2011  |  European Journal of Haematology

Liver Transplantation in an Adult With Sclerosing Cholangitis due to Multisystem Langerhans Cell Histiocytosis

RJ Lee, C Leung, EJ Lim, PW Angus, PS Bhathal, P Crowley, M Gonzales, D Stella, JF Seymour, AG Speer

Journal article  |  2011  |  American Journal of Transplantation

Continued Azacitidine Therapy Beyond Time of First Response Improves Quality of Response in Patients With Higher-Risk Myelodysplastic Syndromes

Lewis R Silverman, Pierre Fenaux, Ghulam J Mufti, Valeria Santini, Eva Hellstrom-Lindberg, Norbert Gattermann, Guillermo Sanz, Alan F List, Steven D Gore, John F Seymour

Journal article  |  2011  |  Cancer

Strategies to optimize collection of hematopoietic stem cells in patients with mantle cell lymphoma receiving hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate (Hyper-CVAD) chemotherapy

Kirsten E Herbert, David S Ritchie, John F Seymour

Journal article  |  2011  |  Leukemia and Lymphoma

Fludarabine, cyclophosphamide, and rituximab chemotherapy followed by rituximab maintenance in follicular lymphoma: high efficacy may come at a cost?

Constantine S Tam, John F Seymour

Journal article  |  2011  |  Leukemia and Lymphoma

Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma

PA Thompson, HM Prince, JF Seymour, D Ritchie, K Stokes, K Burbury, M Wolf, S Peinert, T Joyce, SJ Harrison

Journal article  |  2011  |  Bone Marrow Transplantation

Lymphoproliferative disorders Part 2 - Chronic lymphocytic leukaemia and follicular lymphoma

S Kamel, JF Seymour, HM Prince

Journal article  |  2011  |  Australian Doctor

Rituximab maintenance therapy for follicular lymphoma Reply

Gilles Salles, John Francis Seymour, Fritz Offner, Armando Lopez-Guillermo, Larissa Mege, Herve Tilly

Journal article  |  2011  |  The Lancet

Concomitant FIP1L1--PDGFRA fusion gene and T-cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib

Kate Burbury, Lee Ping Chew, David Westerman, Alberto Catalano, John F Seymour

Journal article  |  2011  |  Leukemia and Lymphoma

An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009

S Lingaratnam, MA Slavin, L Mileshkin, B Solomon, K Burbury, JF Seymour, R Sharma, B Koczwara, SW Kirsa, ID Davis, M Prince, J Szer, C Underhill, O Morrissey, KA Thursky

Journal article  |  2011  |  Internal Medicine Journal

A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment

Senthil Lingaratnam, Leon J Worth, Monica A Slavin, Craig A Bennett, Suzanne W Kirsa, John F Seymour, Andrew Dalton, Bogda Koczwara, H Miles Prince, Mary O'Reilly, Linda Mileshkin, Jeff Szer, Karin A Thursky

Journal article  |  2011  |  Australian Health Review

Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011

S Lingaratnam, MA Slavin, B Koczwara, JF Seymour, J Szer, C Underhill, M Prince, L Mileshkin, M O'Reilly, SW Kirsa, CA Bennett, ID Davis, O Morrissey, KA Thursky

Journal article  |  2011  |  Internal Medicine Journal

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Gilles Salles, John Francis Seymour, Fritz Offner, Armando Lopez-Guillermo, David Belada, Luc Xerri, Pierre Feugier, Reda Bouabdallah, John Vincent Catalano, Pauline Brice, Dolores Caballero, Corinne Haioun, Lars Moller Pedersen, Alain Delmer, David Simpson, Sirpa Leppa, Pierre Soubeyran, Anton Hagenbeek, Olivier Casasnovas, Tanin Intragumtornchai, et al.

Journal article  |  2011  |  The Lancet

Effects of azacitidine compared with conventional care regimens in elderly (>= 75 years) patients with higher-risk myelodysplastic syndromes

John F Seymour, Pierre Fenaux, Lewis R Silverman, Ghulam J Mufti, Eva Hellstrom-Lindberg, Valeria Santini, Alan F List, Steven D Gore, Jay Backstrom, David McKenzie, CL Beach

Journal article  |  2010  |  Critical Reviews in Oncology Hematology

Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy

DA Carney, DA Westerman, CS Tam, A Milner, HM Prince, M Kenealy, M Wolf, EH Januszewicz, D Ritchie, N Came, JF Seymour

Journal article  |  2010  |  Leukemia

Therapy-related myelodysplasia and fludarabine combination therapy - do the benefits justify the risk?

Dennis A Carney, John F Seymour

Journal article  |  2010  |  Leukemia and Lymphoma

Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenstrom macroglobulinemia